Recombinant human anti-PD-1 monoclonal antibody(Hec Biological)

重组抗PD-1全人源单克隆抗体（东阳光）

Report date: 2022/05/07 10:27:36

Base Information

Drug NameRecombinant human anti-PD-1 monoclonal antibody(Hec Biological)
Drug Alias Name重组抗PD-1全人源单克隆抗体注射液
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsEsophageal adenocarcinomaStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDongguan City Hec Biological Medicine Res And Development Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDongguan City Hec Biological Medicine Res And Development Co Ltd
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A